H. Lundbeck A/S – Product Pipeline Review – 2013

Date: April 30, 2013
Pages: 167
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H8C1B9C128CEN
Leaflet:

Download PDF Leaflet

H. Lundbeck A/S – Product Pipeline Review – 2013
H. Lundbeck A/S – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “H. Lundbeck A/S - Product Pipeline Review - 2013” provides data on the H. Lundbeck A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, H. Lundbeck A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from H. Lundbeck A/S and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • H. Lundbeck A/S - Brief H. Lundbeck A/S overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of H. Lundbeck A/S human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of H. Lundbeck A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the H. Lundbeck A/S’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate H. Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of H. Lundbeck A/S in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the H. Lundbeck A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with H. Lundbeck A/S.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of H. Lundbeck A/S and identify potential opportunities in those areas.
H. Lundbeck A/S Snapshot
H. Lundbeck A/S Overview
Key Information
Key Facts
H. Lundbeck A/S – Research and Development Overview
Key Therapeutic Areas
H. Lundbeck A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
H. Lundbeck A/S – Pipeline Products Glance
H. Lundbeck A/S – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
H. Lundbeck A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
H. Lundbeck A/S – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
H. Lundbeck A/S – Drug Profiles
carbamazepine
Product Description
Mechanism of Action
R&D Progress
desmoteplase
Product Description
Mechanism of Action
R&D Progress
KW-6356
Product Description
Mechanism of Action
R&D Progress
LRRK2 Inhibitor
Product Description
Mechanism of Action
R&D Progress
Lu-AA24493
Product Description
Mechanism of Action
R&D Progress
LuAE-58054
Product Description
Mechanism of Action
R&D Progress
LuAF-11167
Product Description
Mechanism of Action
R&D Progress
tedatioxetine
Product Description
Mechanism of Action
R&D Progress
vortioxetine
Product Description
Mechanism of Action
R&D Progress
zicronapine
Product Description
Mechanism of Action
R&D Progress
H. Lundbeck A/S – Pipeline Products by Route of Administration
H. Lundbeck A/S – Pipeline Products By Mechanism of Action
H. Lundbeck A/S – Recent Pipeline Updates
H. Lundbeck A/S - Dormant Projects
H. Lundbeck A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
LuAA-47070
Lu-02750
Lu-35138
Lu-AA24493
LuAA-37096
LuAA-38466
LuAA-39959
LuAA-44608
LuAE-04621
LuAE-58054
ORE-10002
siramesine
H. Lundbeck A/S – Company Statement
H. Lundbeck A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
H. Lundbeck A/S, Recent Developments
H. Lundbeck A/S- Press Release
Apr 08, 2013: Lundbeck Announces Positive Results For Brintellix In Adult Patients With Major Depression And Inadequate Response To SSRI Or SNRI Therapy
Jan 15, 2013: DCGI Serves Notice To Manufacturers And Marketers Of Anti-anxiety Drug Deanxit Over Its Efficacy
Jan 03, 2013: Lundbeck Announces Availability Of Onfi Tablets At Retail Pharmacies
Dec 04, 2010: Lundbeck's Phase III Study Of Clobazam Meets Primary Efficacy Endpoint
Sep 15, 2010: Mochida Files NDA For Anti-depressant Escitalopram In Japan
May 27, 2010: Lundbeck Initiates Enrollment In Phase III program Using Lu AA21004 In Major Depression
May 25, 2010: Lundbeck Plans To Submit NDA For Clobazam For Treatment Of Lennox-Gastaut Syndrome
Apr 06, 2010: Lundbeck Initiates Phase I Clinical Studies Of Lu AE04621 For Treatment Of Parkinson's Disease
Mar 16, 2010: H. Lundbeck's Desmoteplase Enters Clinical Phase II In Japan In Ischaemic Stroke Representing Lundbeck's First Clinical Programme In Japan
Mar 04, 2010: Lundbeck And Takeda To Initiate Phase III Clinical Trials With Lu AA24530
Mar 04, 2010: Lundbeck And Takeda To Initiate Phase III Pivotal Clinical Trials With Lu AA21004
Feb 25, 2010: H. Lundbeck A/S Announces That Data From A Post hoc Analysis Using Desmoteplase In Ischaemic Stroke Presented At The International Stroke Conference
Jan 07, 2010: Mochida And Mitsubishi Sign Co-marketing Agreement For Anti-Depressant Escitalopram In Japan
Financial Deals Landscape
H. Lundbeck A/S, Deals Summary
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For $27 Million
Lundbeck Acquires UK And Ireland Rights Of Nalmefene From Britannia Pharma
Venture Financing
Naurex Raises $38 Million In Series B Financing
Partnerships
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram
H. Lundbeck Enters Into Co-Development Agreement With Proximagen
Lundbeck Enters Into Collaboration With The University Of Massachusetts
H. Lundbeck Enters Into Collaboration With Zenobia Therapeutics
Lundbeck Enters Into Collaboration With Vernalis
H. Lundbeck Enters Into Co-Promotion Agreement With Xian-Janssen
H Lundbeck Enters Into Collaboration With Merck For SYCREST
Genmab Enters Into Co-Development Agreement With Lundbeck
Gladstone Institutes Enters Into Research Agreement With Lundbeck
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
Innovative Medicines Initiative Partners With H. Lundbeck And Kings College London
to-BBB technologies Enters Into Collaboration With H. Lundbeck
H. Lundbeck Enters Into Co-Marketing Agreement With Hanmi Pharma
BioAlliance Pharma Enters Into Co-Promotion Agreement With Lundbeck
Asterand Enters Into Research Agreement With Lundbeck
Lundbeck Signs An Agreement With Aarhus University
GTC Biotherapeutics Enters Into Collaboration Agreement With OVATION Pharma
Lundbeck Enters Into Co-Marketing Agreement With Myriad Genetics
TopoTarget Enters Into Co-Development Agreement With H. Lundbeck
Lundbeck Enters Into Co-Development Agreement With Takeda
Sareum Extends It Co-Development Agreement With H. Lundbeck
Gene Logic Enters Into Co-Development Agreement With H. Lundbeck
Radboud University And Leiden University Enter Into Research Collaboration With Lundbeck
Licensing Agreements
Lundbeck Enters Into Licensing Agreement With Sun Pharma
Ovation Pharma Enters Into Licensing Agreement With Prestwick Pharma
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro
Lundbeck Enters Into Licensing Agreement With Cephalon
Lundbeck Expands Licensing Agreement With PAION For Desoteplase
H Lundbeck Enters Into Licensing Agreement With Kyowa Hakko Kirin For KW-6356
Ore Pharma Enters Into Licensing Agreement With Lundbeck
Lundbeck Enters Into Agreement With Neurim
Lundbeck Expands License Agreement With PAION
Pharmexa Extends Licensing Agreement With Lundbeck
Lundbeck Enters Into Licensing Agreement With Neurim Pharma
Shasun Pharma Enters Into Licensing Agreement With Lundbeck
Gene Logic Enters Into Licensing Agreement With Lundbeck
Asset Transactions
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For $100 Million
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma
Acquisition
Lundbeck Acquires 4.6% Stake In Biotie Therapies For $13 Million
H. Lundbeck Acquires Laboratoire Elaiapharm
H. Lundbeck Acquires LifeHealth
Lundbeck Acquires NeuronIcon
Lundbeck Acquires OVATION Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

H. Lundbeck A/S, Key Information
H. Lundbeck A/S, Key Facts
H. Lundbeck A/S – Pipeline by Indication, 2013
H. Lundbeck A/S – Pipeline by Stage of Development, 2013
H. Lundbeck A/S – Monotherapy Products in Pipeline, 2013
H. Lundbeck A/S – Filed, 2013
H. Lundbeck A/S – Phase III, 2013
H. Lundbeck A/S – Phase II, 2013
H. Lundbeck A/S – Phase I, 2013
H. Lundbeck A/S – Pre-Clinical, 2013
H. Lundbeck A/S – Discovery, 2013
H. Lundbeck A/S – Pipeline By Route of Administration, 2013
H. Lundbeck A/S – Pipeline Products By Mechanism of Action, 2013
H. Lundbeck A/S – Recent Pipeline Updates, 2013
H. Lundbeck A/S - Dormant Developmental Projects,2013
H. Lundbeck A/S - Discontinued Pipeline Products, 2013
H. Lundbeck A/S, Subsidiaries
H. Lundbeck A/S, Deals Summary
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For $27 Million
Lundbeck Acquires UK And Ireland Rights Of Nalmefene From Britannia Pharma
Naurex Raises $38 Million In Series B Financing
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify
ImaginAb Enters Into Co-Development Agreement With H. Lundbeck For CNS Imaging Biologics
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma
Almirall Enters Into Co-Promotion Agreement With Lundbeck For Escitalopram
H. Lundbeck Enters Into Co-Development Agreement With Proximagen
Lundbeck Enters Into Collaboration With The University Of Massachusetts
H. Lundbeck Enters Into Collaboration With Zenobia Therapeutics
Lundbeck Enters Into Collaboration With Vernalis
H. Lundbeck Enters Into Co-Promotion Agreement With Xian-Janssen
H Lundbeck Enters Into Collaboration With Merck For SYCREST
Genmab Enters Into Co-Development Agreement With Lundbeck
Gladstone Institutes Enters Into Research Agreement With Lundbeck
H. Lundbeck Expands Marketing Agreement With Teva Pharma Industries
Innovative Medicines Initiative Partners With H. Lundbeck And Kings College London
to-BBB technologies Enters Into Collaboration With H. Lundbeck
H. Lundbeck Enters Into Co-Marketing Agreement With Hanmi Pharma
BioAlliance Pharma Enters Into Co-Promotion Agreement With Lundbeck
Asterand Enters Into Research Agreement With Lundbeck
Lundbeck Signs An Agreement With Aarhus University
GTC Biotherapeutics Enters Into Collaboration Agreement With OVATION Pharma
Lundbeck Enters Into Co-Marketing Agreement With Myriad Genetics
TopoTarget Enters Into Co-Development Agreement With H. Lundbeck
Lundbeck Enters Into Co-Development Agreement With Takeda
Sareum Extends It Co-Development Agreement With H. Lundbeck
Gene Logic Enters Into Co-Development Agreement With H. Lundbeck
Radboud University And Leiden University Enter Into Research Collaboration With Lundbeck
Lundbeck Enters Into Licensing Agreement With Sun Pharma
Ovation Pharma Enters Into Licensing Agreement With Prestwick Pharma
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro
Lundbeck Enters Into Licensing Agreement With Cephalon
Lundbeck Expands Licensing Agreement With PAION For Desoteplase
H Lundbeck Enters Into Licensing Agreement With Kyowa Hakko Kirin For KW-6356
Ore Pharma Enters Into Licensing Agreement With Lundbeck
Lundbeck Enters Into Agreement With Neurim
Lundbeck Expands License Agreement With PAION
Pharmexa Extends Licensing Agreement With Lundbeck
Lundbeck Enters Into Licensing Agreement With Neurim Pharma
Shasun Pharma Enters Into Licensing Agreement With Lundbeck
Gene Logic Enters Into Licensing Agreement With Lundbeck
Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For $100 Million
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck
Trygg Pharma Completes Acquisition Of Manufacturing Facility In UK From Lundbeck Pharma
Lundbeck Acquires 4.6% Stake In Biotie Therapies For $13 Million
H. Lundbeck Acquires Laboratoire Elaiapharm
H. Lundbeck Acquires LifeHealth
Lundbeck Acquires NeuronIcon
Lundbeck Acquires OVATION Pharma

LIST OF FIGURES

H. Lundbeck A/S – Pipeline by Indication, 2013
H. Lundbeck A/S – Pipeline by Stage of Development, 2013
H. Lundbeck A/S – Monotherapy Products in Pipeline, 2013
H. Lundbeck A/S – Pipeline By Route of Administration, 2013
H. Lundbeck A/S - Pipeline Products By Mechanism of Action, 2013

Ask Your Question

H. Lundbeck A/S – Product Pipeline Review – 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: